Italia markets open in 5 hours 18 minutes

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,4700-0,0100 (-0,29%)
Alla chiusura: 04:00PM EST
3,6400 +0,17 (+4,90%)
Dopo ore: 06:25PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente3,4800
Aperto3,4500
Denaro3,4000 x 1800
Lettera3,8200 x 900
Min-Max giorno3,4200 - 3,4900
Intervallo di 52 settimane2,3800 - 19,0000
Volume39.859
Media Volume41.968
Capitalizzazione24,113M
Beta (5 anni mensile)1,86
Rapporto PE (ttm)N/D
EPS (ttm)-0,3530
Prossima data utili09 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A29,50
  • GlobeNewswire

    Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

    CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,614,380 shares of common stock and warrants to purchase up to an aggregate of 2,614,380 share

  • GlobeNewswire

    Trevena Announces Reverse Stock Split

    CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the “Amendment”) to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 5:01 p.m. ET on Wednesd

  • GlobeNewswire

    Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

    TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of TRV045 in the treatment of epilepsy, based on astrocyte cell culture study PK profile supports anticipated once daily dosing CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicin